Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multi-Center, Phase 4 Study to Evaluate the Effect of Age (Geriatric) and Renal Function on the Safety, Efficacy (Sensitivity, Specificity) and Pharmacokinetics of OctreoScan in Patients Referred for Scintigraphy of All Solid Tumors With a High Suspicion of Containing Somatostatin Receptor Positive Tissue

NCT00944372 is registered in ClinicalTrials.gov with Mallinckrodt as lead sponsor.

NCT NCT00944372
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00944372 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multi-Center, Phase 4 Study to Evaluate the Effect of Age (Geriatric) and Renal Function on the Safety, Efficacy (Sensitivity, Specificity) and Pharmacokinetics of OctreoScan in Patients Referred for Scintigraphy of All Solid Tumors With a High Suspicion of Containing Somatostatin Receptor Positive Tissue
Lead sponsor
Mallinckrodt
Phase
Phase 4
Overall status
Terminated
Start date
July 31, 2003
Completion date
August 31, 2005
Enrollment
150 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors